- Home
- MGRX
MGRX
Mangoceuticals Inc.
as 11-03-2025 4:00pm EST
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 25.2M | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 288.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.32 - $6.15 | Next Earning Date: | 11-14-2025 |
| Revenue: | $516,030 | Revenue Growth: | -40.47% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Mangoceuticals Inc. News
MGRX Breaking Stock News: Dive into MGRX Ticker-Specific Updates for Smart Investing
MT Newswires
5 months ago
Mangoceuticals Files $150 Million Mixed Shelf
TipRanks
5 months ago
Mangoceuticals shares results from field studies on MGX-0024
GlobeNewswire
5 months ago
Mangoceuticals’ Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu
MT Newswires
6 months ago
Mangoceuticals to Acquire Smokeless Technology's Intellectual Property
GlobeNewswire
6 months ago
Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division
ACCESS Newswire
6 months ago
Mangoceuticals Is Reengineering the Self-Care Blueprint with Better Personal Health and Wellness Solutions
ACCESS Newswire
6 months ago
CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape
GlobeNewswire
7 months ago
Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada
Compare MGRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MGRX Mangoceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.